Biotech Values

[dewophile]

HCV
they are not alone in being cryptic about development programs. This has to be the single hottest area of drug development today - and I think everyone is now looking ahead 5+ years for any edge they can get, beyond even efficacy - optimal PK, high potency for coformulation, etc.

PS: I agree with DD that QD dosing is less important since ribavirin is a BID drug, and that coformulation is not as important as in HIV since duration of therapy is finite, BUT - it does appear that these issues are being considered already at this relatively early stage of development, looking ahead to a future in which multiple options with equal efficacy/SE profiles may exist to provide some commercial edge relative to the competition (e.g. itmn looking at ritonavir boosting, idix and others emphasizing potency and potential for QD dosing of compounds (which could be meaningful if there is a significant lead in time until ribavirin dosing), etc.)